Skip to content
MarketScale
‹ Back to IndustriesSciences

The Impact of the Russian ASAT Tests

In this bonus episode of Space to Grow, hosts Charity Weeden and Chris Blackerby  sit down to discuss kinetic ASAT tests in space and possible silver-linings that came from the most recent test. The November 2021 Russian ASAT (Anti-Satellite) test shed unprecedented light onto the space community and is estimated to have produced almost 1700 pieces of…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · AsatBanDebrisRussia
Share

Key takeaways

01

In this bonus episode of Space to Grow, hosts Charity Weeden and Chris Blackerby  sit down to discuss kinetic ASAT tests in space and possible silver-linings that came from the most recent test.

02

The November 2021 Russian ASAT (Anti-Satellite) test shed unprecedented light onto the space community and is estimated to have produced almost 1700 pieces of…

In this bonus episode of Space to Grow, hosts Charity Weeden and Chris Blackerby sit down to discuss kinetic ASAT tests in space and possible silver-linings that came from the most recent test.

The November 2021 Russian ASAT (Anti-Satellite) test shed unprecedented light onto the space community and is estimated to have produced almost 1700 pieces of debris in the 600km range, close to Earth, which was spread throughout other orbital regimes.

Not only did this test launch international attention on debris in space, but it reaffirmed uncertainty in operating in space for many private and public space entities. Space debris, or space “junk” as it is commonly referred to, can range from outdated satellites, to tiny fragments of broken up objects, similar to what the Russian ASAT test created.

The junk clogs up orbital pathways and can cause unforeseen structural damage to orbiting or launching objects. As such, many companies, including Astroscale have condemned ASAT tests in the industry as irresponsible behavior.

While space debris continues to orbit, Blackerby highlighted some silver-linings on the situation, “It’s awareness…when do we see the non-space media and community get in…We had recognition by politicians around the world that this was bad.”

Though not catastrophic in the near-term, the test created so much debris that the resulting awareness in the international community can be viewed as a positive aspect, but not one that the space industry wants to repeat as a normative action.

On ASAT tests, Weeden was firm that we can not allow this activity to, “live in the space environment.” Space actors can not continue doing these tests and apologizing as if they do not have any future, long-term consequences.

“I’m hopeful this will galvanize some sort of ASAT ban,” said Weeden. Given the international attention, the need to get rid of space trash is front and center and a ban on ASAT tests will help keep space accessible to all.

More in This Series

About the author

CB
Chris Blackerby

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512